• Facebook Social Icon

© 2014 by Rx Bandz, LLC. 

About

Since our inception, Rx Bandz has been focused on providing an innovative next generation solution for patients who carry self injectable medication. 
Rx Bandz Team

We have assembled a team of talented and experienced individuals who have the knowledge, skill and experience required to create the next innovative and disruptive auto-injector design capable of delivering a wide range of therapeutic injectable medications.

CORPORATE

Jessica Walsh - Founder, CEO

Innovator and seasoned entrepreneur, former project manager for world leading construction and engineering firm, business and technical experience from senior management positions in technology, business development, digital marketing and team management, Six Sigma process improvements. Frustrated Epipen user.

Larry Kunstadt Ph.D. -  Chief Corporate Officer

Ph.D.(biology), MBA (finance) 15 yrs. in academia, 30 years on Wall St. financing biomedical companies (venture capital & investment banking).  Taught “New Venture Management” in the Stern MBA program at NYU.  Formerly on Business Advisory Board, Alzheimer’s Drug Discovery Foundation, a Lauder family charity.  Currently co-head of NY chapter of Society of Physician Entrepreneurs and on Medical Review Board of IPRO (dialysis safety).

Myrna Walsh - Chief Administrative Officer

Former Executive Director of Massachusetts hospital system foundation. Published author. Successfully raised millions of dollars for healthcare in grants. Municipal capital budget advisory board member. Launched hospice from concept to Medicare ready. Frustrated EpiPen user.

Harsha Murthy – Director, Licensing

Senior pharmaceutical executive with extensive experience in licensing to big pharma and direct experience with companies in the auto-injector space. Previous roles include founding private equity firms/funds (Consummate Capital and Konanda Pharma Partners) that invested in pharmaceuticals / medical devices, leadership roles at large and start up pharmaceutical companies (King Pharmaceuticals and Eyetech Pharmaceuticals), financial industry (GE Capital, U.S. SEC and kRoad Ventures) and legal (Davis Polk & Wardwell and Latham & Watkins). B.A degree form Duke University and J.D. from Stanford Law School.

James DeAngelis - Strategic Advisor

25 years of corporate financial experience in companies with environmental and biotech focus; 18 years as C-Level Executive with strategic development in intellectual property including manufacturing processes, laboratory analysis for early FDA approval applications, multi-million dollar exits and IPO.

MEDICAL

Dr. Michael Blaiss MD, FACAAI - Chief Medical Officer

Clinical Professor of Pediatrics and Medicine, University of Tennessee Health Science Center. Executive Medical Director, American College of Allergy, Asthma, and Immunology. He was a past Medical Director for Pfizer and Merck.

Obinna Anosike, MD- Medical Research

Rutgers Robert Wood Johnson Medical School. Held position as a M1 course facilitator 

guiding learning, brainstorming, and problem solving of medical case based problems. 

Masters in Biomedical Science DNJ-Stratford.

Perry Molinoff, MD. - Pharmaceutical Advisor

Dr. Molinoff's background includes more than thirty years of experience in both the academic and industrial sectors. He is professor of Pharmacology Emeritus, University of Pennsylvania. He is also Chairman of the Innovation Support Center Panel, Harrington Discovery Institute. Previously he directed research at Palatin Technologies and Bristol-Meyers Squibb Pharmaceutical Research Institute. He has served on the boards of multiple private and public pharmaceutical companies and published extensively, including six text books and over 230 manuscripts.

Julie DeAngelis Ph.D. - Health Economics Advisor

18 years diverse pharmaceutical experience with leadership positions within marketing, clinical development and health economics and outcomes research with Astellas Pharmaceuticals.

DEVELOPMENT/ MANUFACTURING

Stephen Harhen- Chief Engineering Officer 

Bio-materials and mechanical engineer. He previously was a Research and Development Engineer for Ethicon, a Johnson and Johnson Company. He currently is a PhD candidate (Mechanical Engineering) at Villanova University and holds a MS (Biomedical Engineering) from New Jersey Institute of Technology, and a BS (Biomedical Engineering) from Rutgers University School of Engineering.

John Dines Dinesen - Chief Manufacturing Officer

Founder and President of IMSCE Engineering with more than 30 years engineering experience and 15 years within design, prototype, and building complex medical instruments and manufacturing systems in Europe, Asia and the US.

David Dlugo – Quality Management

Broad experience consulting on regulatory strategy and compliance. Editor of Biotech Daily Post for Medical Device/Combination Products/Pharma. Owner, D6 Product Development Consultants, guiding companies through product development in regulated environments. Oversees Technical Operation, US WorldMeds, managing combination products and medical devices, including compliance documentation. BS Mechanical Engineering.

Lori Baker MA – Quality Management

Over 20 years hands-on quality experience with GCP research and development; PK and toxicology GLP studies; commercial and investigational product GMP processes (compound/fill/labeling/packaging/serialization); and quality review of test method development with analysis of release and stability data.  Dosage form knowledge with solution for injection, tablet, oral suspension and inhaled, along with drug/device combination delivery via single and multiple use auto- and manual injectors and nebulizer/vial system.  FDA, ICH and EMA regulation-based audits on GXP vendors, clinical investigators and internal groups.

E Paul Harhen - Engineering Advisor

39 years experience in with engineering, medical device product design/testing for manufacture, support including clinical trials for FDA submission. Successfully developed numerous products and brought them to launch. Holds 28 US patent